Gain Therapeutics, Inc. Income Statement
GANX|4 years of annual SEC 10-K data (FY2021-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Gain Therapeutics, Inc. reported $55,180 in revenue and $22M in net loss for FY2024. Revenue has grown at a 24.1% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $55.2K | $140.1K | $165.0K | $28.9K |
| SG&A Expense | $10.8M | $9.5M | $6.8M | $1.2M |
| R&D Expense | $11.5M | $8.4M | $7.2M | $2.3M |
| Operating Income | -$22.3M | -$17.8M | -$13.8M | -$3.5M |
| Interest Expense | - | $375.4K | $12.5K | $0 |
| Income Tax | $79.3K | $93.0K | $4.0K | $5.4K |
| Net Income | -$22.3M | -$17.6M | -$13.9M | -$3.6M |
| EPS (Basic) | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
| EPS (Diluted) | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
| Shares Outstanding | 16.2M | 11.9M | 11.9M | 3.5M |
| Operating Margin | -40328.3% | -12688.1% | -8379.8% | -12047.5% |
| Profit Margin | -40354.3% | -12555.1% | -8418.9% | -12387.7% |